Advertisement

Cambridge gene-therapy company bluebird bio has added Arch Venture Partners to its roster of backers for its latest round that brought in $30 million in financing, which the company describes in a press release as all part of its master plan to move its gene therapy platform quickly forward.

Previous investors Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group all participated in the new funding round, in addition to newcomer Arch Venture Partners. The funding deal places Arch Venture managing director Steven Gillis on bluebird bio’s board of directors.

SOURCE

Advertisement
Advertisement